← Back to News
Research

Targeted Immunotherapy Combo Shows Strong Results in Relapsed Mantle Cell Lymphoma

By David Jaquette, co-founder and Board Member ·

A Phase 2 clinical trial published online in Blood on 21 April 2026 reports encouraging results for a combination of two targeted immunotherapies — mosunetuzumab and polatuzumab vedotin — in people with relapsed or refractory mantle cell lymphoma (MCL) who have already been through several lines of treatment, including a BTK inhibitor. Across 42 patients, 88% responded to the regimen and 79% achieved a complete response, meaning no detectable cancer at the end of treatment.

For patients living with MCL, this is meaningful because it could add another line of therapy after BTK inhibitors, where options are still limited. The new study suggests that a time-limited, outpatient regimen built around the immune system — rather than another round of chemotherapy or a more intensive cellular therapy — can produce deep remissions even in patients with the highest-risk disease.

Below, we walk through what the trial tested, how the two drugs work, what the results showed, and what it means for the MCL community.

What was tested

The trial enrolled 42 adults with relapsed or refractory MCL who had received at least two prior lines of therapy, including a BTK inhibitor (the class of drugs that includes ibrutinib, acalabrutinib and zanubrutinib). The median patient had already been through three different treatments.

Importantly, this was a high-risk group. Among the 42 patients:

  • 48% had a TP53 aberration — a mutation or deletion in the TP53 gene that is associated with much shorter survival in MCL.
  • 67% had a Ki-67 proliferation index of 50% or higher — a marker that the lymphoma cells are dividing rapidly.
  • 48% had blastoid or pleomorphic histology — more aggressive forms of MCL under the microscope.

In the past, patients with these features have responded less favorably to standard treatments. They were not excluded from this trial; they were the majority of it.

The regimen itself was designed to be practical:

  • Mosunetuzumab was given as a subcutaneous injection (under the skin) for 17 cycles.
  • Polatuzumab vedotin was given as an intravenous infusion for the first 6 cycles only.

Treatment was delivered in the outpatient setting and was time-limited — patients are not expected to stay on therapy indefinitely.

How the two drugs work

Mosunetuzumab and polatuzumab vedotin attack lymphoma cells through two completely different mechanisms. Combining them is the central scientific idea of the trial.

Mosunetuzumab is a bispecific antibody. It has two binding ends: one grabs onto CD20, a protein on the surface of B-cell lymphomas (including MCL), and the other grabs onto CD3, a protein on the patient’s own T cells. By holding the two cells side-by-side, mosunetuzumab uses the patient’s own immune system to kill the cancer.

Polatuzumab vedotin is an antibody-drug conjugate. It is a different type of weapon: an antibody that recognises CD79b, another protein found on B-cell lymphomas, attached to a potent chemotherapy payload. The antibody acts like a homing device — it finds the lymphoma cell and delivers the chemotherapy directly inside it, sparing most healthy tissue.

The reason combining these two makes sense is that they don’t depend on the same biology to work. If a lymphoma cell can resist one mechanism, it may still be vulnerable to the other.

What the results showed

After a median follow-up of 15.9 months, the headline results were:

  • Overall response rate: 88.1%
  • Complete response rate: 78.6%
  • Median progression-free survival: 18.6 months (at the point of publication)

Crucially, the authors report that efficacy was consistent across the high-risk subgroups described above.

Why this matters for MCL patients

For patients whose MCL has returned after a BTK inhibitor, the choices today are still limited. CAR T-cell therapy with Tecartus — which the FDA fully approved for adult relapsed/refractory MCL on 2 April 2026 — is highly effective but requires several weeks of cell manufacturing, hospital admission, and is only delivered at certified centres.

The mosunetuzumab + polatuzumab vedotin regimen offers something different:

  • It is given off-the-shelf, with no manufacturing wait.
  • It is fixed-duration, so patients have a defined end-point.
  • It is administered subcutaneously and intravenously in the outpatient setting.
  • It produced a 79% complete response rate in a heavily pretreated, high-risk population.

Caveats and what’s next

We want to set realistic expectations. This is a Phase 2 study in 42 patients. The follow-up is still relatively short, so the long-term durability of these remissions is not yet known. And the combination is not yet FDA-approved for MCL — patients interested in this regimen today would need to access it through a clinical trial or, eventually, an off-label or expanded-access pathway. Larger, longer studies will be needed to confirm these findings and define exactly where this combination fits in the MCL treatment sequence.

Yet, for our community, the takeaway is one of optimism. A new mechanism — a bispecific antibody paired with an antibody-drug conjugate — has shown that even in MCL patients with TP53 aberrations, high Ki-67, blastoid disease, or prior CAR T, deep remissions are achievable with a defined, outpatient course of therapy. That is real progress.

If you or a loved one are facing relapsed MCL, talk with your haematologist about the post-BTKi treatment options that are right for your specific disease, including clinical trials.

Sources

Share this article